Benefit of Treatment With Sebelipase-Alfa in a 63-Year-Old Patient With Advanced Liver and Atherosclerotic Disease Due to Lysosomal Acid Lipase Deficiency (LAL-D)
暂无分享，去创建一个
C. Datz | B. Paulweber | V. Ratziu | D. Neureiter | E. Aigner | A. Feldman
[1] J. Frampton. Sebelipase Alfa: A Review in Lysosomal Acid Lipase Deficiency , 2016, American Journal of Cardiovascular Drugs.
[2] G. Enns,et al. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. , 2015, The New England journal of medicine.
[3] Kees Hovingh,et al. Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction. , 2014, Atherosclerosis.
[4] R. Desnick,et al. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. , 2013, Journal of hepatology.